Cholesterolemia control in Spain, 2000: A tool for cardiovascular disease prevention;Control de la colesterolemia en Espana, 2000: Un instrumento para la prevencion cardiovascular

Revista Clinica Espanola

Volumn 200, Issue 9, 2000, Pages 494-515

  Plaza Perez I ^a   Villar Alvarez F ^b   Mata Lopez P ^c   Perez Jimenez F ^d   Maiquez Galan A ^e   Casasnovas Lenguas, J A ^f   Banegas Banegas, J R ^h   Tomas Abadal L ^g   Rodriguez Artalejo F ^h   Gil Lopez E ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b MINISTERIO DE SANIDAD Y CONSUMO   (Spain)

^c Unidad de Lipidos   (Spain)

^d Universidad de Cordoba   (Spain)

^e Centro de Salud Nazaret   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h Hospital La Paz ^*

Author keywords

Cardiovascular diseases; Cholesterolemia; Primary prevention; Secondary prevention

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEMOGRAPHY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MEDICAL DECISION MAKING; PERIODICITY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; SPAIN; TREATMENT INDICATION;

EID: 0033678554     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(00)70705-3     Document Type: Article

References (125)

1. Multiple Risk Factor Intervention Trial Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1.465-1.477.
2. Simons LA. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986; 57;5G-10G.
3. Shepherd J, Cobe S, Ford I, Isles C, Ross A, Macfarlane P, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1.301-1.307.
4. Banegas Banegas JR, Villar Álvarez F, Pérez de Andrés C, Jiménez García-Pascual R, Gil López E, Muñiz García J, et al. Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años. Rev San Hig Pub 1993; 67:419-445.
5. The WHO MONICA Project. A worldwide monitoring system for cardiovascular diseases: cardiovascular mortality and risk factors in selected communities. World Health Stat Annu 1989; 27-149.
6. Muñiz J, Juane R, Hervada J, López Rodríguez I, Castro Beiras A. Concentraciones séricas de colesterol en la población gallega de 40-69 años de edad. Clin Invest Arterioscl 1991; 3:143-148.
7. Aranda P, Villar J. Estudio epidemiológico andaluz sobre factores de riesgo vascular. Estudio Al-Andalus 90. Sevilla: Consejería de Salud, 1993.
8. Rodríguez JC, Calonge S, Bichara G. Prevalencia de los factores de riesgo de cardiopatía isquémica en la isla de Lanzarote. Med Clin (Barc) 1993; 101:45-50.
9. Tormo Díaz MJ, Navarro Sánchez C, Chirlaque López MD, Pérez Flores D. Factores de riesgo cardiovascular en la región de Murcia, España. Rev Esp Salud Pública 1997; 71:515-529.
10. Masía R, Pena A, Marrugat J, Sala J, Pavesi M, Covas J, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Community Health 1998; 52:707-715.
11. García Closas R, Serra Majem L, Chacón Castro P, Olmos Castellvell M, Ribas Barba L, Salleras L. Distribución de la concentración de lípidos séricos en una muestra representativa de la población adulta de Cataluña. Med Clin (Barc) 1999; 113:6-12.
12. Segura Fragoso A, Rius Mery G. Factores de riesgo cardiovascular en una población rural de Castilla-La Mancha. Rev Esp Cardiol 1999; 52: 577-588.
13. Tomás-Abadal L, Varas Lorenzo C, Bernades-Bernat E, Balaguer-Vintró I. Coronary risk factors and a 20-year incidence of coronary heart disease and mortality in a Mediterranean industrial population. Eur Heart J 1994; 15:1.028-1.036.
14. López Miranda J, Ordovás JM, Pérez Jiménez F. Interacción genesdieta como determinante de las concentraciones plasmáticas de colesterol. Med Clin (Barc) 1998; 111:546-551.
15. Keys A, Anderson JT, Grande F. Prediction of serum cholesterol responses of man to changes in fats in the diet. Lancet 1957; 2:959-966.
16. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet, IV. Particular saturated fatty acids in the diet. Metabolism 1965; 14:776-787.
17. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr 1965; 17:281-295.
18. Ros Rahola E, Fisac C, Pérez-Heras A. ¿Qué es realmente la dieta mediterránea? FMC 1998; 5:557-571.
19. Varela G, Moreiras O, Carbajal A, Campo M. Estudio Nacional de Nutrición y Alimentación 1991 Tomo I. Encuesta de Presupuestos Familiares 1990-1991. Madrid: Instituto Nacional de Estadística, 1995.
20. Serra-Majem L, Ribas L, Lloveras G, Salleras L. Changing patterns of fat consumption in Spain. Eur J Clin Nutr 1993; 47 (suppl 1):13-20.
21. Rodríguez Artalejo F, Banegas JR, Graciani MA, Hernández Vecino R, Rey Calero J. El consumo de alimentos y nutrientes en España en el período 1940-1988. Análisis de su consistencia con la dieta mediterránea. Med Clin (Barc) 1996; 106:161-168.
22. Rodríguez Artalejo F, Graciani MA, Banegas JR, Martín-Moreno JM, Sabaté J, Rey Calero J. El consumo de alimentos y nutrientes en España en el período 1940-1988 (y II). Un estudio comparativo de las principales fuentes de información sobre consumo alimentario. Med Clín (Barc) 1996; 107:446-452.
23. Gordon DJ, Probstfield JL, Garrison JR, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
24. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999; 144:285-301.
25. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1.029-1.036.
26. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77:1.179-1.184.
27. Villar Álvarez F, Banegas JR, Rodríguez Artalejo F, Rey Calero J. Mortalidad cardiovascular en España y sus Comunidades Autónomas (1975-1992). Med Clín (Barc) 1998; 110:321-327.
28. Medrano MJ, Almazán J, Sierra MJ, Olalla MT. Situación epidemiológica de las enfermedades cardiovasculares arterioescleróticas (I): mortalidad y morbilidad. Bol Epidemiol Semanal 1998; 6:149-153.
29. Villar Álvarez F, Banegas Banegas JR. La mortalidad cardiovascular en España. Rev San Hig Pub 1991; 65:5-7.
30. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. Task Force on the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18:1.231-1.248.
31. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353:1.547-1.557.
32. Pérez G, Pena A. Sala J, Roset P, Masiá R, Marrugat J. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992. Int J Epidemiol 1998; 27:599-604.
33. Balaguer Vintró I. Estrategias en el control de los factures de riesgo coronario en la prevención primaria y secundaria. Rev Esp Cardiol 1998; 51 (suppl 6):30-35.
34. Rodríguez Artalejo F, Banegas Banegas JR, De Andrés Manzano B, del Rey Calero J. Principios de la prevención cardiovascular. Med Clín (Barc) 1999; 112:459-464.
35. Wood D, De Backer G, Faergerman O, Graham I, Mancia G. Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19:1.434-1.503.
36. Kannel WB, Castelli W, Gordon T. Cholesterol in the prediction of coronary heart disease: new perspectives based on the Framingham Study. Ann Intern Med 1979; 90:1.985-1.991.
37. Rose G. La estrategia de la medicina preventiva. Barcelona: MassonSalvat, 1994.
38. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An update coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-362.
39. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silvershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1.837-1.847.
40. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panell II). Circulation 1994; 89:1.329-1.445.
41. Ministerio de Sanidad y Consumo. Sociedad Española de Cardiología. Consenso para el control de la colesterolemia en Españia. Madrid: MSC, 1990.
42. Grupo de Trabajo de Prevención Cardiovascular. Guía de prevención cardiovascular. Madrid: SEMFYC, 1996.
43. Villar Álvarez F, Maiques Galán A, Brotons Cuixart C, Torcal Laguna J. Lorenzo Piqueres A, Vilaseca Canals J, et al. Recomendaciones preventivas cardiovasculares: aplicaciones prácticas del riesgo cardiovascular. Programa de actividades preventivas y de promoción de la salud. Aten Primaria 1999; 24 (suppl 1):66-75.
44. Lago Deibe F, Abad Vivas Pérez JJ, Álvarez Cosmea A, Blasco Valle M, Alamo Alonso AJ, Llor Vila C, et al. Dislipemias. Manejo de las dislipemias en atención primaria. Recomendaciones SEMFYC, Madrid: Emisa, 1997.
45. Doll R, Peto R, Wheatly K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309:901-911.
46. Comité Nacional para la Prevención del Tabaquismo. Libro blanco sobre el tabaquismo en España. Barcelona: Glosa, 1998.
47. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease. A meta-analysis of epidemiologic studies. N Engl J Med 1999; 340:920-926.
48. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
49. Aranda P, Banegas JR, Barajas R, Luque M, Rodicio JL. Diagnosis and therapeutic management of hypercholesterolemic Spanish hypertensives. J Hypertens 1999; 17 (suppl 3):192A.
50. Hayakawa H, Raij L. Relationship between hypercholesterolemia, endotelial dysfunction and hypertension. J Hypertens 1999; 17:611-619.
51. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
52. Laakso M, Lehto S. Epidemiology of macrovascular disease and diabetes. Diabetes Rev 1997; 5:294-315.
53. González Santos P, Herrera Pombo JL, Ascaso JF, Escobar Jiménez F, Gómez Gerique JA, Jiménez Perepérez JA, et al. Dislipemia diabética: documento de consenso de la Sociedad Española de Diabetes y la Sociedad Española de Arteriosclerosis. Av Diabetol 1998; 14:33-43.
54. American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care 2000; 23 (suppl 1):57-60.
55. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620.
56. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type II diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-233.
57. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225-232.
58. WHO. Human genetics programme. Familial hypercholesterolemia. Ginebra; WHO, 1998.
59. Bruin T, Castro M, Dallinga-Thie G, Erkelens W. Familial combined hyperlipidemia-do we understand the pathophysiology and genetics? En: Betteridge J, ed. Lipids: current perspectives. Londres: Martin Dunitz Ltd, 1996; 101-114.
60. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973; 52:1.533-1.543.
61. Berenson GS, Srinivasan SR, Bao WB, Newman WP, Tracy RE, Wattigney WA, for the Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998; 338:1.650-1.656.
62. Plaza Pérez I, Grupo de Expertos de las Sociedades Española de Arteriosclerosis. Cardiología. Pediatría, Nutrición y Medicina Preventiva. Informe sobre el colesterol en niños y adolescentes españoles. Clin Invest Arterioscl 1991; 3:47-66.
63. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332:1.758-1.766.
64. Rodriguez Artalejo F. La enfermedad cardiovascular en la mujer. Aten Primaria 1998; 22 (suppl 1):200-205.
65. Mosca L, Grundy S, Judelson D, King K, Limacher M, Oparil S, et al. Guide to preventive cardiology for women. Circulation 1999; 99:2.480-2.484.
66. La Rosa JC. Dyslipoproteinemia in women and the elderly. Med Clin North Am 1994; 78:163-180.
67. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990; 113:916-920.
68. Sociedad Española de Arteriosclerosis. Dieta y enfermedades cardiouasculares: recomendaciones de la Sociedad Española de Arteriosclerosis. Clin Invest Arterioscl 1994; 6:43-61.
69. Aranceta J. Objetivos nutricionales y guias dietéticas. Propuesta de la SENC para la población española. En: Serra Majem Ll, Aranceta Bartrina J, Mataix Verdú J, eds. Documenta de consenso. Guías alimentarias para la población española. Barcelona: SG, 1995.
70. Hertog M, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch Intern Med 1995; 155:381-386.
71. Gay K, Puska P, Jordan P, Moser U. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nut 1991; 53:326S-334S.
72. Sierra MJ, Medrano MJ, Almazán J, Olalla MT, López-Abente G. Variaciones provinciales en el contenido de folatos, B12 y B6 y mortalidad cardiovascular. Rev Esp Salud Pública 1988; 72 (suppl):145.
73. Carmena R, Ascaso JF, Serrano S, Martínez-Valls J, Arbona C, Sánchez-Juan C. Modificaciones de las lipoproteinas y apolipoproteínas plasmáticas inducidas por aceite de oliva y aceite de girasol en sujetos normales. Clin Invest Arterioscl 1989; 1:10-15.
74. Mata P, Álvarez-Sala E, Rubio M, Nuño J, Oya M. Effects of long-term monounsaturated-vs polyunsaturated-enriched diets on lipoproteins in healthy men and women. Am J Clin Nutr 1992; 55:846-850.
75. Pérez-Jiménez F, Espino A, López F, Blanco J, Ruiz V, Prada J, et al. Lipoprotein concentrations in normolipidemic males consuming oleic acid-rich diets from two different sources: olive oil and oleic acid-rich sunflower oil. Am J Clin Nutr 1994; 62:769-775.
76. Mata P, Alonso R, López-Farre A, Ordovas JM, Lahoz C, Garcés C, et al. Effect of dietary fat saturation on LDL oxidation and monocyte adhesion to human endothelial cells in vitro. Arterioscler Thromb Vasc Biol 1996; 16:1.347-1.355.
77. Mata P, Varela O, Alonso R, Lahoz C, Oya M, Badimon L. Monounsaturated and polyunsaturated n-6 fatty acid-enriched diets modify LDL oxidation and decrease human coronary smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol 1997; 17:2.088-2.095.
78. Espino A, López Miranda J, Castro P, Rodriguez M, López-Segura F, Blanco A, et al. Monounsaturated fatty acid enriched diets lower plasma insulin levels and blood pressure in healthy young men. Nutr Metab Cardiovasc Dis 1996; 6:147-154.
79. Ruiz-Gutiérrez V, Muriana FJ, Guerrero A, Cert AM, Villar J. Plasma lipids, erythrocyte membrane lipids and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources. J Hypertens 1996; 14:1.483-1.490.
80. Lahoz C, Alonso R, Ordovas JM, López A, Oya M, Mata P. Effects of dietary fat saturation on eicosanoid production, platelet agregation and blood pressure. Eur J Clin Invest 1997; 27:780-787.
81. López-Segura F, Velasco F, López-Miranda J, Castro P, López R, Blanco A, et al. Monounsaturated fatty acid-enriched diet decreases plasma plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 1996; 16:82-88.
82. Rodríguez Artalejo F, De Andrés Manzano B, Banegas Banegas JR, Guallar Castillón P, Villar Álvarez F, Rey Calero J. La disminución del consumo moderado de alcohol se ha asociado a un descenso de los bebedores excesivos en España en el período 1987-1993. Med Clín (Barc) 1999; 113:371-373.
83. a ed). Baltimore: Williams and Wilkins, 1996.
84. Ministerio de Sanidad y Consumo. Prevención del tabaquismo. Ayuda a tu paciente a cortar por lo sano. Madrid: MSC, 1998.
85. Marrugat J, Elosua R, Covas MI, Molina L, Rubiés-Prat J. Amount and intensity of physical activity, physical fitness, and serum lipids in men. Am J Epidemiol 1996; 143:562-569.
86. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA 1996; 276:241-246.
87. Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1.615-1.622.
88. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998; 81:912-917.
89. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction of incidence of CHD. JAMA 1984; 251:351-364.
90. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1.237-1.245.
91. Grupo de Trabajo de la Sociedad Española de Arteriosclerosis. En: Merino Sánchez J. Gómez Gerique JA, eds. Control del paciente dislipémico y factures que afectan al cumplimiento terapéutico. Madrid: IDEPSA, 1998.
92. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1.339-1.342.
93. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1.700-1.707.
94. Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long term coronary prognosis after initial myocardial infarction: the Framingham heart study. Am J Epidemiol 1989; 130:469-480.
95. Rossouw J, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323:1.112-1.119.
96. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990; 323:946-955.
97. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
98. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326:242-250.
99. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326:310-318.
100. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1.383-1.389.
101. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335:1.001-1.009.
102. The long term intervention with pravastatin in ischaemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1.349-1.357.
103. The Post CABG Trials Investigators. The effect of aggresive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The post coronary artery bypass graft trial investigators. N Engl J Med 1997; 336:153-162.
104. Pitt B, Waters D, Brown WV, Van Boven J, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341:70-76.
105. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials. JAMA 1997; 278:313-321.
106. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97:946-952.
107. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418.
108. Plaza I, Gómez JA. Cambio de actitud de los cardiólogos españoles respecte al tratamiento hipolipemiante en prevención secundaria de la cardiopatía isquémica. Clin Invest Arterioscl 1999; 11:8-15.
109. Velasco JA, Cosín J, López Sendón JL, De Teresa E, Oya M, Carrasco JL, et al. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol 1997; 50:406-415.
110. Stafford RS, Blumenthal D, Pasternak RC. Variation in cholesterol management practices of US. Physicians. J Am Coll Cardiol 1997; 29:139-146.
111. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European action on secondary prevention through intervention to reduce events. Eur Heart J 1997; 18:1.569-1.582.
112. Singh RB, Rastogi SS, Verma R, Bolaki L, Singh R. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992; 304:1.015-1.019.
113. Burr ML, Fehily M, Gilbert JF, Rogers S, Holliday MR, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: diet and reinfarction trial (DART). Lancet 1989; 2:757-761.
114. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779-785.
115. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsatured fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-455.
116. The International Task Force for Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk. Nutr Metab Cardiovasc Dis 1998; 8:205-271.
117. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99:3.227-3.233.
118. WHO. Needs and priorities in cardiac rehabilitation and secondary prevention in patients with coronary artery disease. WHO Technical Report Series 831. Ginebra: WHO, 1993.
119. Grupo de Trabajo de Rehabilitación Cardiaca de la Sociedad Española de Cardiología. Rehabilitación del paciente coronario. Prevención secundaria. Rev Esp Cardiol 1995; 48:643-649.
120. Plaza I, Velasco JA, Maroto JM. Prevención secundaria y rehabilitación cardiaca en España. Rev Esp Cardiol 1996; 49:549-553.
121. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157:2.413-2.446.
122. Maroto Montero JM, De Pablo Zarzosa C, Morales Duran MD, Artigao Ramírez R. Rehabilitación cardiaca. Análisis coste-efectividad. Rev Esp Cardiol 1996; 49:753-758.
123. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999; 99:1.173-1.182.
124. Comisión de Lípidos y Lipoproteínas de la Sociedad Española de Quimica Clínica. Métodos recomendados para la determinación de la concentración de colesterol en suero y plasma y en otros especimenes biológicos. Química Clínica 1994; 13:496-503.
125. Gómez Gerique JA, Montoya MT. Estandarización de la medición de lípidos y lipoproteínas. Clin Invest Arterioscl 1999; 11:28-47.